Sab Biotherapeutics Inc (SABS)

Precedente Chiudi:

Volume 24 ore:

Relative Volume:

Capitalizzazione di mercato:

Utile/perdita netta:

Rapporto P/E:

Flusso di cassa netto:

1 W Prestazione:

1M Prestazione:

6M Prestazione:

1 anno Prestazione:

Intervallo 1D:

Intervallo di 1 settimana:

Portata 52W:

Sab Biotherapeutics Inc Stock (SABS) Company Profile

Sab Biotherapeutics Inc

305-845-2813

777 W 41ST ST, MIAMI BEACH

Prossima data di guadagno

Ultimi documenti SEC

SABS's Discussions on Twitter

Sab Biotherapeutics Inc Stock (SABS) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2021-11-05	Iniziato	Chardan Capital Markets	Buy

Sab Biotherapeutics Inc Borsa (SABS) Ultime notizie

Sab Biotherapeutics Inc Azioni (SABS) Dati Finanziari

Sab Biotherapeutics Inc Azioni (SABS) insider trading

Commercio interno	Relazione	Data	Transazione	Costo	#Azioni	Valore ($)	#Azioni Totale
King Michael	CHIEF FINANCIAL OFFICER	Nov 30 '23	Buy	0.90	5,000	4,500	5,000
Reich Samuel J	Executive Chairman	Nov 29 '23	Buy	0.89	11,000	9,842	219,001

Sab Biotherapeutics Inc (SABS)

Sab Biotherapeutics Inc Stock (SABS) Company Profile

Sab Biotherapeutics Inc Stock (SABS) Upgrades & Downgrades

Sab Biotherapeutics Inc Borsa (SABS) Ultime notizie

SAB Biotherapeutics, Inc. (NASDAQ:SABSW) Short Interest Update - Defense World

SAB BIO CEO to Participate in Fireside Chat at 2024 Cantor Global Healthcare Conference - GlobeNewswire

SAB BIO CEO to Participate in Fireside Chat at 2024 Cantor Global Healthcare Conference - StockTitan

SAB Biotherapeutics (NASDAQ:SABS) Given “Buy” Rating at Chardan Capital - Defense World

SAB BIO Provides SAB-142 Clinical Trial Progress Update at - GlobeNewswire

SAB BIO Provides SAB-142 Clinical Trial Progress Update at the European Association for the - The Bakersfield Californian

SAB BIO Provides SAB-142 Clinical Trial Progress Update at the European Association for the Study of Diabetes Annual Meeting - StockTitan

SAB BIO to Present at the European Association for the Study of Diabetes 60th Annual Meeting - GlobeNewswire

SAB BIO to Present at the European Association for the Study of Diabetes 60th Annual Meeting - StockTitan

SAB Biotherapeutics (NASDAQ:SABS) Coverage Initiated by Analysts at Oppenheimer - Defense World

How To Buy SAB Biotherapeutics, Inc. Stock Online in August 2024 - Traders Union

Influenza Pipeline Drugs 2024 | Moderna, SAB Biotherapeutics, ENA Respiratory Pty Ltd, Codagenix, AlloVir, Osivax, CureVac AG - Barchart

Chardan Capital Analysts Boost Earnings Estimates for SAB Biotherapeutics, Inc. (NASDAQ:SABS) - Defense World

SAB Biotherapeutics (NASDAQ:SABS) Receives Buy Rating from HC Wainwright - Defense World

SAB Biotherapeutics (NASDAQ:SABS) Stock Rating Reaffirmed by Chardan Capital - Defense World

SABS stock touches 52-week low at $2.3 amid market challenges - Investing.com

SAB BIO Announces Second Quarter 2024 Financial Results and Provides Company Updates - GlobeNewswire

SAB BIO Announces Second Quarter 2024 Financial Results and Provides Company Updates - StockTitan

Seasonal Influenza Treatment Market Size 2032 | SAb - openPR

SAB BIO Announces Founding of Clinical Advisory Board to Guide the Development of SAB-142 for Type 1 Diabetes - GlobeNewswire

SAB BIO Announces Founding of Clinical Advisory Board to Guide the Development of SAB-142 for Type 1 Diabetes - StockTitan

SAB BIO Appoints Lucy To as Chief Financial Officer - citybiz

SAB BIO Appoints Lucy To as Chief Financial Officer - GlobeNewswire

SAB BIO Appoints Lucy To as Chief Financial Officer - StockTitan

SAB Biotherapeutics (NASDAQ:SABS) Trading Down 0.4% - American Banking and Market News

SAB Biotherapeutics (NASDAQ:SABS) Trading Down 0.4% - Defense World

MarketBeat June market recap - SiouxFalls.Business

SAB Biotherapeutics to Present at the Ladenburg Thalmann Annual Healthcare Conference 2021 - Quantisnow

Big Cypress Acquisition Corp. Reports Ladenburg Conference Presentation by Planned Merger Partner SAB Biotherapeutics - Quantisnow

SAB Biotherapeutics Announces Publication of Preclinical Data Demonstrating SAB-185 Effectively Neutralizes SARS ... - Quantisnow

SAB Biotherapeutics Announces Nonclinical Data Demonstrating SAB-185 Potently Neutralizes Delta and Lambda ... - Quantisnow

SAB Biotherapeutics to List on Nasdaq through Merger with Big Cypress Acquisition Corp., Advancing Unique Human ... - Quantisnow

Reviewing SAB Biotherapeutics (NASDAQ:SABS) & Quantum Genomics Société Anonyme (OTCMKTS:QNNTF) - Defense World

Cathie Wood's ARK ETF focuses on PagerDuty, 10X Genomics stock By Investing.com - Investing.com

Tenaya Therapeutics Announces Director Resignation By Investing.com - Investing.com

CSP Inc insider buys shares worth over $23,000 - Investing.com

Kintara Therapeutics restructures share designations By Investing.com - Investing.com

Broker Revenue Forecasts For SAB Biotherapeutics, Inc. (NASDAQ:SABS) Are Surging Higher - Yahoo New Zealand News

Need To Know: The Consensus Just Cut Its SAB Biotherapeutics, Inc. (NASDAQ:SABS) Estimates For 2022 - Yahoo Sport Australia

SAB Bio updates brand to reflect focus on type 1 diabetes therapy By Investing.com - Investing.com Australia

SAB Bio updates brand to reflect focus on type 1 diabetes therapy By Investing.com - Investing.com UK

SAB Biotherapeutics rebrands as SAB BIO; reaffirms full-year outlook (NASDAQ:SABS) - Seeking Alpha

SAb Biotherapeutics Rebrands as SAB BIO - GlobeNewswire

SAb Biotherapeutics Rebrands as SAB BIO | SABSW Stock News - StockTitan

SAB Biotherapeutics to Present at the American Diabetes Association 84th Scientific Sessions - ForexTV.com

SAB Biotherapeutics to Present at the American Diabetes Association 84th Scientific Sessions - GlobeNewswire

SAB Biotherapeutics to Present at the American Diabetes Association 84th Scientific Sessions - Yahoo Finance

SAB Biotherapeutics to Present at the American Diabetes Association 84th Scientific Sessions - StockTitan

BVF Inc. IL Acquires New Stake in SAB Biotherapeutics, Inc. (NASDAQ:SABS) - Defense World

FDA Greenlights First Drug in Nearly a Decade for Rare Liver Disease - BioSpace

Brookline Capital starts SAB Biotherapeutics stock with $8 PT, buy rating By Investing.com - Investing.com

Sab Biotherapeutics Inc Azioni (SABS) Dati Finanziari

Reddito

Reddito netto

Flusso di cassa

EPS

Sab Biotherapeutics Inc Azioni (SABS) insider trading

Simile a SABS